Pfizer

KKR acquires Pfizer’s Capsugel

Tuesday, August 2, 2011 11:01 AM

Pfizer has completed the sale of its Capsugel business to an affiliate of Kohlberg Kravis Roberts & Co. (KKR), following the receipt of required regulatory clearances, including in the U.S. and the European Union. Under the terms of the previously announced agreement, KKR acquired Capsugel for $2.375 billion in cash.

More... »

Critics raise concerns over research, incentives of European pediatric exclusivity regulations

Monday, August 1, 2011 08:00 AM

Regulations introduced four years ago in Europe to encourage research into medicines for children have lead to important therapeutic breakthroughs for pediatric patients.  Yet concerns also have been raised about how well the system works.

More... »

Insufficient advisory board members due to conflict-of-interest rules

Wednesday, July 27, 2011 01:19 PM

Conflict-of-interest rules restricting scientists with financial ties to drug and device- makers from advising U.S. regulators may loosen next year, said FDA Commissioner Margaret Hamburg, according to Bloomberg News.

More... »

Icon acquires Firecrest Clinical, adding portal technology to boost site quality while reducing errors and costs

Monday, July 25, 2011 08:02 AM

As large pharmaceutical companies scrutinize the pack of mid- and top-tier CROs to determine who wins the coveted strategic-partnership agreements, there’s a mad scramble among CROs to differentiate themselves from one another and stand out as efficient, high quality, exciting and deserving.

More... »

Pfizer to open research center in San Francisco’s Mission Bay

Friday, July 22, 2011 01:28 PM

Boosting Mission Bay's goal of becoming a hub for cutting-edge biotech, Pfizer has plans to establish a research center at the 303-acre former industrial site overlooking San Francisco Bay, according to the San Francisco Chronicle.

More... »

Pfizer acquires Icagen

Wednesday, July 20, 2011 01:57 PM

Pfizer and Icagen have entered into a definitive merger agreement. Pfizer, which currently owns approximately 11% of Icagen’s fully diluted shares, will acquire the remaining 8.3 million shares at a price of $6 per share. The aggregate transaction value, including the value of the shares currently owned by Pfizer, is approximately $56 million.

More... »

PPD shares rise on takeover rumors

Monday, July 18, 2011 01:51 PM

Shares of CRO Pharmaceutical Product Development (PPD) rose 16% to levels not touched in more than two-and-a-half years on Monday, a day after a Wall Street Journal report said the company was looking to sell itself, reported Reuters.

More... »

DVS Sciences raises $14.6 million

Friday, July 15, 2011 10:58 AM

The Ontario Institute for Cancer Research (OICR) and DVS Sciences have announced DVS Sciences has completed a $14.6 million series A financing. DVS, a Toronto-based spinoff from the University of Toronto, invented and manufactures instrumentation that enables paradigm-shifting biological research with potential clinical applications that include personalized medicine.

More... »

FDA proposes targeted drug testing guidelines

Wednesday, July 13, 2011 10:53 AM

Targeted drugs or therapies up for regulatory approval would have to be reviewed simultaneously with the diagnostic devices they rely on, according to a proposed policy issued by the FDA, according to Reuters.

More... »

FDA eases rules for Alzheimer’s experiments to speed new treatments for dementia

Tuesday, July 12, 2011 12:35 PM

The FDA is making it easier to test new Alzheimer’s drugs, hoping to speed progress toward new treatments for the mind-robbing disease, according to an Associated Press report.

More... »